๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · China

Advanced Solid Tumors Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.9 Suzhou Suncadia Biopharmaceuticals Co., Ltd.7 Jiangsu HengRui Medicine Co., Ltd.6 Shanghai Hengrui Pharmaceutical Co., Ltd.6 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.5
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Advanced Solid Tumors trials in China

183 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
NCT06773091Advanced Solid Tumors
DrugsNK042·Fludarabine·Cyclophosphamide
Shanghai NK Cell Technology Co., LTD
Phase 1
76
Beijing
2025-02-07
Recruiting
SKB445 for Injection in Solid Tumors
NCT06826040Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
126
Jinan
2025-02-05
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
NCT06770569Advanced Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1
100
Beijing
2025-01-21
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
NCT06801470Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
Phase 1
137
Tianjin
2025-01-08
Recruiting
A Phase โ…  Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
NCT07229898Advanced Solid Tumors
DrugGEN-725
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Recruiting
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
NCT07046650Advanced Solid Tumors
Sheng Zhang
Phase 2
84
Shanghai
2025-01-01
Recruiting
A Study of HDM2006 in Patients With Advanced Solid Tumor
NCT07377591Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
48
Shanghai
2024-12-31
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
NCT06736327Advanced Solid Tumors
DrugSKB500
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
180
Jilin City
2024-12-13
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Study of SIGX1094R in Patients With Advanced Solid Tumors
NCT06739291Advanced Solid Tumors
Signet Therapeutics
Phase 1
102
Beijing
2024-12-12
Recruiting
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
NCT06643754Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
115
Chongqing
2024-12-10
Recruiting
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
NCT06686745Advanced Solid Tumors
DrugOlaparib
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Shanghai, Chongqing
2024-12-06
Not yet open
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828Advanced Solid Tumors
DrugSHR-4602
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-12
Recruiting
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
NCT06618651Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
162
Chengdu
2024-11-13
Active, closed
A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors
NCT06610227Advanced Solid Tumors
NING LI
Phase EARLY_PHASE1
18
Beijing
2024-11-08
Recruiting
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT06598735Advanced Solid Tumors
DrugHRS-4508
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
290
Beijing
2024-11-05
Not yet open
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
NCT06594874Non-Small Cell Lung Cancer, Advanced Solid Tumors
DrugsHS-10370·Adebrelimab·Pemetrexed·Cisplatin
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
350
Wuhan
2024-10-31
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
NCT06656390Advanced Cancer, Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Recruiting
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
NCT06605222Advanced Solid Tumors
DrugSHR-7787
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
201
Shanghai
2024-10-04
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
DrugTislelizumab
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
NCT06520488Advanced Solid Tumors
DrugHRS-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
118
Shanghai
2024-08-09
Recruiting
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
NCT07093970Advanced Solid Tumors
DrugMRG006A
Lepu Biopharma Co., Ltd.
Phase 1/2
343
Beijing, Shanghai
2024-07-24
Recruiting
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836Advanced Solid Tumors, HCC
DrugIMM2510
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
108
Shanghai
2024-07-23
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Recruiting
A Study of SKB518 in Patients With Advanced Solid Tumors
NCT06428331Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2024-07-04
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT06474455Advanced Solid Tumors
DrugsAlmonertinib Mesilate·SHR-9839·SHR-A1921·SHR-A2009
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
156
Zhengzhou, Hangzhou
2024-07-02
Recruiting
A Trial of SHR-4849 in Advanced Solid Tumors
NCT06443489Advanced Solid Tumors
DrugSHR-4849
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
80
Jilin City
2024-06-26
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
NCT06417554Advanced Solid Tumors
DrugsSHR-A2102·Disitamab Vedotin·Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
80
Beijing
2024-05-27
Recruiting
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
NCT06376136Advanced Solid Tumors
Bio-Thera Solutions
Phase 1/2
216
Guangzhou
2024-05-08
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
DrugAMT-116
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Active, closed
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
NCT06394414Advanced Solid Tumors
DrugSerplulimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Active, closed
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
NCT06341114Advanced Solid Tumors
DrugsBAT1308·BAT8008
Bio-Thera Solutions
Phase 1/2
112
Hangzhou
2024-04-12
Recruiting
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT06336707Advanced Solid Tumors
DrugsHS-20089·Cisplatin/carboplatin·Adebrelimab·Bevacizumab
Hansoh BioMedical R&D Company
Phase 1
1,048
Shanghai
2024-04-11
Recruiting
A Study for HSK39775 in Participants With Solid Tumors
NCT06314373Advanced Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
Phase 1/2
243
Shanghai
2024-03-07
Recruiting
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580Malignant Melanoma, Advanced Solid Tumors
DrugAMT-253
Multitude Therapeutics Inc.
Phase 1/2
96
Beijing
2024-01-31
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
DrugsVVD-133214·Bevacizumab·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Recruiting
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
NCT06214143Advanced Solid Tumors
DrugT3011
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Recruiting
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
NCT06208410Advanced Solid Tumors
DrugsDalpiciclib Isetionate·JS105·Pyrotinib Maleate·Fluzoparib
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2
306
Zhengzhou
2024-01-11
Recruiting
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
NCT06158477Advanced Solid Tumors
Chengdu JOYO pharma Co., Ltd.
Phase 1
75
Shanghai
2024-01-01
Recruiting
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
NCT06094556Advanced Solid Tumors
DrugSHR-1826
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
240
Guangzhou
2023-12-25
Not yet open
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
NCT06183736Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
Phase 2
98
Beijing
2023-12-20
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Not yet open
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
NCT06134531Advanced Solid Tumors
DrugMR001
Nanfang Hospital, Southern Medical University
Phase 1
31
Guangzhou
2023-11
Recruiting
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
NCT05944224Advanced Solid Tumors
DrugsSPH4336·Cadonilimab
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xiโ€™an
2023-10-17
Active, closed
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
NCT05951608Advanced Solid Tumors
DrugsAK127·Ivonescimab
Akeso
Phase 1/2
216
Harbin
2023-10-16
Recruiting
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116Advanced Solid Tumors
DrugsBNT324·Abiraterone·Itraconazole·Enzalutamide
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT05867420Advanced Solid Tumors
DrugsFruquintinib·Docetaxel·Bevacizumab·Paclitaxel
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
DrugsINCA33890·ADG126·Folfiri·Folfox
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Active, closed
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
NCT05914376Advanced Solid Tumors
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
NCT05881525Advanced Solid Tumors
DrugsAldesleukin·Fludarabine·Nab-paclitaxel·Cyclophosphamide
TCRCure Biopharma Ltd.
Phase 1
18
Chongqing
2023-06-01
Recruiting
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
NCT05773820Advanced Solid Tumors
DrugWJB001
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
210
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Recruiting
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709Advanced Solid Tumors
DrugSHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Not yet open
A Study of KM501 in Patients With Solid Tumors
NCT05804864Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
96
Tianjin
2023-04
Active, closed
A Phase I Clinical Study of the Safety๏ผŒ Tolerability๏ผŒPharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
NCT05781048Advanced Solid Tumors
DrugHRS-6209
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Recruiting
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
NCT05823285Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Recruiting
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
NCT05541822Advanced Solid Tumors
DrugLazertinib
Abion Inc
Phase 2
178
2023-01-17
Recruiting
Phase 1 Trial of KH617
NCT05667194Advanced Solid Tumors
Sichuan Honghe Biotechnology Co., Ltd.
Phase 1
45
Beijing
2022-12-26
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Recruiting
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
NCT05620017Advanced Solid Tumors
DrugBAT8008
Bio-Thera Solutions
Phase 1
182
Chongqing, Hangzhou
2022-11-30
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT05537740Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
129
Guangzhou, Changchun, Linyi
2022-10-11
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
DrugHRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
NCT05502393Advanced Solid Tumors
DrugsJS107·Toripalimab·Capecitabine·Oxaliplatin
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Recruiting
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
NCT05688605Advanced Solid Tumors
DrugsBecotatug Vedotin·Pucotenlimab
Lepu Biopharma Co., Ltd.
Phase 1/2
18
Guangzhou, Changsha
2022-06-30
Recruiting
A Study of SKB315 in Patients With Advanced Solid Tumors
NCT05367635Advanced Solid Tumors
DrugSKB315
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
246
Tianjin
2022-03-16
Active, closed
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
NCT05114759Advanced Solid Tumors
DrugSHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xiโ€™an
2022-01-04
Recruiting
ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors
NCT07793214Advanced Solid Tumors, Advanced Solid Tumors Cancer
Zhejiang Hospital
Observational
500
Hangzhou
2022-01-01
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Recruiting
A Study of GC101 TIL in Advanced Solid Tumors (TR)
NCT04967833Advanced Solid Tumors
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
20
Shanghai
2021-04-22
Recruiting
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
NCT04778839Advanced Solid Tumors
DrugPaclitaxel
First Affiliated Hospital of Zhejiang University
Phase 1
98
Hanzhou
2021-03-04
Recruiting
A Study of KC1036 in Patients with Advanced Solid Tumors
NCT04387916Advanced Solid Tumors
DrugKC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1
207
Chongqing, Haikou, Chengdu
2020-09-04
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
120
Guangzhou
2019-10-30
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03893955Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
DrugsABBV-927·Budigalimab·Nab-paclitaxel·Carboplatin
AbbVie
Phase 1
150
2019-05-21
Rows per page Showing 101–183 of 183
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/advanced-solid-tumors?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 183 of those studies listing the condition Advanced Solid Tumors.

How many Advanced Solid Tumors trials are recruiting in China?

132 of the 183 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 35 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.